{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,20]],"date-time":"2026-02-20T02:48:35Z","timestamp":1771555715500,"version":"3.50.1"},"reference-count":84,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,11,27]],"date-time":"2021-11-27T00:00:00Z","timestamp":1637971200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000897","name":"Cystic Fibrosis Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000897","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100013845","name":"Pediatric Endocrine Society","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013845","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jctejournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Clinical & Translational Endocrinology"],"published-print":{"date-parts":[[2022,3]]},"DOI":"10.1016\/j.jcte.2021.100283","type":"journal-article","created":{"date-parts":[[2021,12,13]],"date-time":"2021-12-13T12:12:50Z","timestamp":1639397570000},"page":"100283","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["Cystic fibrosis related liver disease and endocrine considerations"],"prefix":"10.1016","volume":"27","author":[{"given":"Jordan S.","family":"Sherwood","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jagdeesh","family":"Ullal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katherine","family":"Kutney","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kara S.","family":"Hughan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jcte.2021.100283_b0005","doi-asserted-by":"crossref","first-page":"S29","DOI":"10.1016\/S1569-1993(11)60006-4","article-title":"Best practice guidance for the diagnosis and management of cystic fibrosis-associated liver disease","volume":"10","author":"Debray","year":"2011","journal-title":"J Cyst Fibros"},{"issue":"2","key":"10.1016\/j.jcte.2021.100283_b0010","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.jcf.2012.11.010","article-title":"Cirrhosis and other liver disease in cystic fibrosis","volume":"12","author":"Flass","year":"2013","journal-title":"J Cyst Fibros"},{"issue":"8","key":"10.1016\/j.jcte.2021.100283_b0015","doi-asserted-by":"crossref","first-page":"13529","DOI":"10.3390\/ijms150813529","article-title":"Cystic fibrosis related liver disease\u2013another black box in hepatology","volume":"15","author":"Staufer","year":"2014","journal-title":"Int J Mol Sci"},{"issue":"5","key":"10.1016\/j.jcte.2021.100283_b0020","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1002\/cld.583","article-title":"Cystic fibrosis-related liver diseases: new paradigm for treatment based on pathophysiology","volume":"8","author":"Fiorotto","year":"2016","journal-title":"Clin Liver Dis (Hoboken)"},{"issue":"10","key":"10.1016\/j.jcte.2021.100283_b0025","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1002\/lt.24842","article-title":"Liver transplantation in adult cystic fibrosis: Clinical, imaging, and pathological evidence of obliterative portal venopathy","volume":"23","author":"Hillaire","year":"2017","journal-title":"Liver Transpl"},{"issue":"5","key":"10.1016\/j.jcte.2021.100283_b0030","doi-asserted-by":"crossref","first-page":"e11","DOI":"10.1016\/j.jcf.2017.03.006","article-title":"Liver disease in cystic fibrosis presents as non-cirrhotic portal hypertension","volume":"16","author":"Witters","year":"2017","journal-title":"J Cyst Fibros"},{"issue":"10","key":"10.1016\/j.jcte.2021.100283_b0035","doi-asserted-by":"crossref","first-page":"2134","DOI":"10.1016\/j.cgh.2018.10.046","article-title":"Obliterative portal venopathy without cirrhosis is prevalent in pediatric cystic fibrosis liver disease with portal hypertension","volume":"17","author":"Wu","year":"2019","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"1","key":"10.1016\/j.jcte.2021.100283_b0040","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.jcf.2016.08.002","article-title":"Prevalence of elevated liver enzymes in children with cystic fibrosis diagnosed by newborn screen","volume":"16","author":"Woodruff","year":"2017","journal-title":"J Cyst Fibros"},{"issue":"10","key":"10.1016\/j.jcte.2021.100283_b0045","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1001\/jama.2009.1295","article-title":"Genetic modifiers of liver disease in cystic fibrosis","volume":"302","author":"Bartlett","year":"2009","journal-title":"JAMA"},{"issue":"6","key":"10.1016\/j.jcte.2021.100283_b0050","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1002\/hep.1840360613","article-title":"Liver disease in cystic fibrosis: A prospective study on incidence, risk factors, and outcome","volume":"36","author":"Colombo","year":"2002","journal-title":"Hepatology"},{"issue":"6","key":"10.1016\/j.jcte.2021.100283_b0055","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1016\/j.jhep.2004.08.006","article-title":"Epidemiology of liver disease in cystic fibrosis: a longitudinal study","volume":"41","author":"Lamireau","year":"2004","journal-title":"J Hepatol"},{"issue":"2","key":"10.1016\/j.jcte.2021.100283_b0060","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1002\/hep.29217","article-title":"Adult-onset cystic fibrosis liver disease: diagnosis and characterization of an underappreciated entity","volume":"66","author":"Koh","year":"2017","journal-title":"Hepatology"},{"issue":"8","key":"10.1016\/j.jcte.2021.100283_b0065","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1016\/j.cgh.2016.03.041","article-title":"Features of severe liver disease with portal hypertension in patients with cystic fibrosis","volume":"14","author":"Stonebraker","year":"2016","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"1","key":"10.1016\/j.jcte.2021.100283_b0070","doi-asserted-by":"crossref","first-page":"34","DOI":"10.4254\/wjh.v10.i1.34","article-title":"Risk factors for hepatic steatosis in adults with cystic fibrosis: similarities to non-alcoholic fatty liver disease","volume":"10","author":"Ayoub","year":"2018","journal-title":"World J Hepatol"},{"issue":"1","key":"10.1016\/j.jcte.2021.100283_b0075","doi-asserted-by":"crossref","DOI":"10.1186\/s12890-018-0766-6","article-title":"Clinical expression of cystic fibrosis in a large cohort of Italian siblings","volume":"18","author":"Terlizzi","year":"2018","journal-title":"BMC Pulm Med"},{"issue":"6","key":"10.1016\/j.jcte.2021.100283_b0080","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1097\/MCP.0b013e3282f10a16","article-title":"Liver disease in cystic fibrosis","volume":"13","author":"Colombo","year":"2007","journal-title":"Curr Opin Pulm Med"},{"issue":"4","key":"10.1016\/j.jcte.2021.100283_b0085","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1097\/MPG.0000000000001676","article-title":"Cystic Fibrosis-related Liver Disease: Research Challenges and Future Perspectives","volume":"65","author":"Debray","year":"2017","journal-title":"J Pediatr Gastroenterol Nutr"},{"issue":"4","key":"10.1016\/j.jcte.2021.100283_b0090","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1016\/j.jcf.2020.05.002","article-title":"A longitudinal assessment of non-invasive biomarkers to diagnose and predict cystic fibrosis-associated liver disease","volume":"19","author":"Karnsakul","year":"2020","journal-title":"J Cyst Fibros"},{"issue":"5","key":"10.1016\/j.jcte.2021.100283_b0095","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1002\/hep.28016","article-title":"Aspartate aminotransferase to platelet ratio and fibrosis-4 as biomarkers in biopsy-validated pediatric cystic fibrosis liver disease","volume":"62","author":"Leung","year":"2015","journal-title":"Hepatology"},{"key":"10.1016\/j.jcte.2021.100283_b0100","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.jpeds.2019.12.033","article-title":"Heterogeneous liver on research ultrasound identifies children with cystic fibrosis at high risk of advanced liver disease: interim results of a prospective observational case-controlled study","volume":"219","author":"Siegel","year":"2020","journal-title":"J Pediatr"},{"issue":"3","key":"10.1016\/j.jcte.2021.100283_b0105","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/j.jcf.2020.06.006","article-title":"The emergence of elastography for cystic fibrosis liver disease","volume":"19","author":"Masand","year":"2020","journal-title":"J Cyst Fibros"},{"issue":"12","key":"10.1016\/j.jcte.2021.100283_b0110","doi-asserted-by":"crossref","first-page":"2561","DOI":"10.1016\/j.cgh.2019.03.015","article-title":"Accuracy of transient elastography data combined with APRI in detection and staging of liver disease in pediatric patients with cystic fibrosis","volume":"17","author":"Lewindon","year":"2019","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"1","key":"10.1016\/j.jcte.2021.100283_b0115","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1002\/hep.24014","article-title":"Importance of hepatic fibrosis in cystic fibrosis and the predictive value of liver biopsy","volume":"53","author":"Lewindon","year":"2011","journal-title":"Hepatology"},{"issue":"9","key":"10.1016\/j.jcte.2021.100283_b0120","first-page":"CD000222","article-title":"Ursodeoxycholic acid for cystic fibrosis-related liver disease","volume":"9","author":"Cheng","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"issue":"4","key":"10.1016\/j.jcte.2021.100283_b0125","doi-asserted-by":"crossref","first-page":"1648","DOI":"10.1002\/hep.30148","article-title":"Cystic fibrosis liver disease: outcomes and risk factors in a large cohort of French patients","volume":"69","author":"Bo\u00eblle","year":"2019","journal-title":"Hepatology"},{"issue":"12","key":"10.1016\/j.jcte.2021.100283_b0130","doi-asserted-by":"crossref","first-page":"761","DOI":"10.4254\/wjh.v11.i12.761","article-title":"Lumacaftor\/ivacaftor therapy is associated with reduced hepatic steatosis in cystic fibrosis patients","volume":"11","author":"Kutney","year":"2019","journal-title":"World J Hepatol"},{"issue":"4","key":"10.1016\/j.jcte.2021.100283_b0135","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1097\/MPG.0000000000002867","article-title":"Cystic fibrosis-related liver disease: the next challenge","volume":"71","author":"Baker","year":"2020","journal-title":"J Pediatr Gastroenterol Nutr"},{"issue":"3","key":"10.1016\/j.jcte.2021.100283_b0140","first-page":"192","article-title":"Elexacaftor-Tezacaftor-Ivacaftor: the first triple-combination cystic fibrosis transmembrane conductance regulator modulating therapy","volume":"25","author":"Ridley","year":"2020","journal-title":"J Pediatr Pharmacol Ther"},{"issue":"3","key":"10.1016\/j.jcte.2021.100283_b0145","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/j.jcf.2018.11.009","article-title":"Cirrhosis associated with decreased survival and a 10-year lower median age at death of cystic fibrosis patients in the Netherlands","volume":"18","author":"Pals","year":"2019","journal-title":"J Cyst Fibros"},{"issue":"2","key":"10.1016\/j.jcte.2021.100283_b0150","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.cld.2018.12.008","article-title":"Hepatic manifestations of cystic fibrosis","volume":"23","author":"Sakiani","year":"2019","journal-title":"Clin Liver Dis"},{"issue":"3","key":"10.1016\/j.jcte.2021.100283_b0155","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/j.jpeds.2004.05.051","article-title":"Cystic fibrosis-associated liver disease: a population-based study","volume":"145","author":"Corbett","year":"2004","journal-title":"J Pediatr"},{"issue":"1","key":"10.1016\/j.jcte.2021.100283_b0160","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.jcf.2014.05.013","article-title":"Outcome in patients with cystic fibrosis liver disease","volume":"14","author":"Rowland","year":"2015","journal-title":"J Cyst Fibros"},{"issue":"6","key":"10.1016\/j.jcte.2021.100283_b0165","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1097\/MPG.0000000000002694","article-title":"Cystic fibrosis-related liver disease is associated with increased disease burden and endocrine comorbidities","volume":"70","author":"Singh","year":"2020","journal-title":"J Pediatr Gastroenterol Nutr"},{"issue":"3","key":"10.1016\/j.jcte.2021.100283_b0170","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.1210\/jc.2004-1629","article-title":"Guide to bone health and disease in cystic fibrosis","volume":"90","author":"Aris","year":"2005","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.jcte.2021.100283_b0175","doi-asserted-by":"crossref","first-page":"317","DOI":"10.3389\/fendo.2019.00317","article-title":"Vitamin D binding protein, total and free vitamin D levels in different physiological and pathophysiological conditions","volume":"10","author":"Bikle","year":"2019","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"4","key":"10.1016\/j.jcte.2021.100283_b0180","doi-asserted-by":"crossref","first-page":"496","DOI":"10.3390\/nu10040496","article-title":"Vitamin D and the liver-correlation or cause?","volume":"10","author":"Keane","year":"2018","journal-title":"Nutrients"},{"issue":"4","key":"10.1016\/j.jcte.2021.100283_b0185","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/j.jcf.2007.11.006","article-title":"Undercarboxylated osteocalcin and bone mass in 8\u201312 year old children with cystic fibrosis","volume":"7","author":"Fewtrell","year":"2008","journal-title":"J Cyst Fibros"},{"issue":"6","key":"10.1016\/j.jcte.2021.100283_b0190","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1016\/j.dld.2017.01.155","article-title":"Vitamin K status in cystic fibrosis patients with liver cirrhosis","volume":"49","author":"Krzy\u017canowska","year":"2017","journal-title":"Dig Liver Dis"},{"key":"10.1016\/j.jcte.2021.100283_b0195","first-page":"CD008482","article-title":"Vitamin K supplementation for cystic fibrosis","volume":"6","author":"Jagannath","year":"2020","journal-title":"Cochrane Database Syst Rev"},{"issue":"3","key":"10.1016\/j.jcte.2021.100283_b0200","doi-asserted-by":"crossref","first-page":"660","DOI":"10.3945\/ajcn.2010.29350","article-title":"Suboptimal vitamin K status despite supplementation in children and young adults with cystic fibrosis","volume":"92","author":"Dougherty","year":"2010","journal-title":"Am J Clin Nutr"},{"issue":"3","key":"10.1016\/j.jcte.2021.100283_b0205","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/j.bpg.2005.11.006","article-title":"Cystic fibrosis: nutritional consequences and management","volume":"20","author":"Dodge","year":"2006","journal-title":"Best Pract Res Clin Gastroenterol"},{"issue":"4","key":"10.1016\/j.jcte.2021.100283_b0210","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1007\/s00394-020-02358-2","article-title":"Choline in cystic fibrosis: relations to pancreas insufficiency, enterohepatic cycle, PEMT and intestinal microbiota","volume":"60","author":"Bernhard","year":"2021","journal-title":"Eur J Nutr"},{"issue":"1","key":"10.1016\/j.jcte.2021.100283_b0215","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.jcf.2019.05.007","article-title":"Highlights from the nutrition guidelines for cystic fibrosis in Australia and New Zealand","volume":"19","author":"van der Haak","year":"2020","journal-title":"J Cyst Fibros"},{"issue":"3","key":"10.1016\/j.jcte.2021.100283_b0220","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1038\/nrgastro.2015.226","article-title":"Cystic fibrosis from the gastroenterologist's perspective","volume":"13","author":"Ooi","year":"2016","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"6","key":"10.1016\/j.jcte.2021.100283_b0225","doi-asserted-by":"crossref","first-page":"482","DOI":"10.5001\/omj.2019.90","article-title":"Cystic fibrosis liver disease: know more","volume":"34","author":"Al Sinani","year":"2019","journal-title":"Oman Med J"},{"key":"10.1016\/j.jcte.2021.100283_b0230","first-page":"CD000406","article-title":"Oral calorie supplements for cystic fibrosis","volume":"11","author":"Smyth","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"issue":"1","key":"10.1016\/j.jcte.2021.100283_b0235","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1002\/ppul.21322","article-title":"The effects of an intensive behavior and nutrition intervention compared to standard of care on weight outcomes in CF","volume":"46","author":"Stark","year":"2011","journal-title":"Pediatr Pulmonol"},{"issue":"7","key":"10.1016\/j.jcte.2021.100283_b0240","first-page":"CD008190","article-title":"Appetite stimulants for people with cystic fibrosis","author":"Chinuck","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.jcte.2021.100283_b0245","unstructured":"Cyproheptadine, in LiverTox: Clinical and Research Information on Drug-Induced Liver Injury. 2012: Bethesda (MD)."},{"issue":"5","key":"10.1016\/j.jcte.2021.100283_b0250","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1530\/eje.0.1480551","article-title":"Sex steroids and body composition in men with cystic fibrosis","volume":"148","author":"Leifke","year":"2003","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.jcte.2021.100283_b0255","doi-asserted-by":"crossref","first-page":"S95","DOI":"10.1016\/j.jcf.2019.08.024","article-title":"Female reproductive health in cystic fibrosis","volume":"18","author":"Hughan","year":"2019","journal-title":"J Cyst Fibros"},{"issue":"2","key":"10.1016\/j.jcte.2021.100283_b0260","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1111\/jgh.12695","article-title":"Testosterone in men with advanced liver disease: abnormalities and implications","volume":"30","author":"Sinclair","year":"2015","journal-title":"J Gastroenterol Hepatol"},{"issue":"4","key":"10.1016\/j.jcte.2021.100283_b0265","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1210\/jcem-67-4-639","article-title":"Differential binding of testosterone and estradiol to isoforms of sex hormone-binding globulin: selective alteration of estradiol binding in cirrhosis","volume":"67","author":"Terasaki","year":"1988","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"10.1016\/j.jcte.2021.100283_b0270","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1002\/ppul.22822","article-title":"Serum insulin-like growth factor-1 (IGF-1) during CF pulmonary exacerbation: trends and biomarker correlations","volume":"49","author":"Gifford","year":"2014","journal-title":"Pediatr Pulmonol"},{"issue":"2","key":"10.1016\/j.jcte.2021.100283_b0275","doi-asserted-by":"crossref","first-page":"e520","DOI":"10.1210\/clinem\/dgaa792","article-title":"Relationship of IGF-1 and IGF-Binding Proteins to Disease Severity and Glycemia in Nonalcoholic Fatty Liver Disease","volume":"106","author":"Stanley","year":"2021","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"10.1016\/j.jcte.2021.100283_b0280","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.jhep.2008.02.013","article-title":"Growth hormone-stimulated IGF-1 generation in cirrhosis reflects hepatocellular dysfunction","volume":"49","author":"Assy","year":"2008","journal-title":"J Hepatol"},{"issue":"4","key":"10.1016\/j.jcte.2021.100283_b0285","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1007\/BF03346823","article-title":"Insulin-like growth factor I: a good indicator of functional hepatocellular capacity in alcoholic liver cirrhosis","volume":"14","author":"Caufriez","year":"1991","journal-title":"J Endocrinol Invest"},{"issue":"4","key":"10.1016\/j.jcte.2021.100283_b0290","doi-asserted-by":"crossref","first-page":"233","DOI":"10.14740\/jocmr2761w","article-title":"Insulin-like growth factor-1 deficiency and cirrhosis establishment","volume":"9","author":"de la Garza","year":"2017","journal-title":"J Clin Med Res"},{"issue":"5","key":"10.1016\/j.jcte.2021.100283_b0295","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1053\/gast.1997.v113.pm9352864","article-title":"Growth hormone therapy in patients with cirrhosis: a pilot study of efficacy and safety","volume":"113","author":"Donaghy","year":"1997","journal-title":"Gastroenterology"},{"issue":"8","key":"10.1016\/j.jcte.2021.100283_b0300","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1515\/JPEM.2008.21.8.793","article-title":"Growth hormone therapy improves growth in children with cystic fibrosis related liver disease","volume":"21","author":"Stalvey","year":"2008","journal-title":"J Pediatr Endocrinol Metab"},{"key":"10.1016\/j.jcte.2021.100283_b0305","doi-asserted-by":"crossref","first-page":"1423462","DOI":"10.1155\/2016\/1423462","article-title":"Diagnosis and management of cirrhosis-related osteoporosis","volume":"2016","author":"Santos","year":"2016","journal-title":"Biomed Res Int"},{"issue":"5","key":"10.1016\/j.jcte.2021.100283_b0310","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1111\/j.1651-2227.2007.00250.x","article-title":"Liver disease as risk factor for cystic fibrosis-related diabetes development","volume":"96","author":"Minicucci","year":"2007","journal-title":"Acta Paediatr"},{"issue":"6","key":"10.1016\/j.jcte.2021.100283_b0315","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1016\/j.jcf.2019.04.015","article-title":"Incidence and risk factors of paediatric cystic fibrosis-related diabetes","volume":"18","author":"Perrem","year":"2019","journal-title":"J Cyst Fibros"},{"issue":"4","key":"10.1016\/j.jcte.2021.100283_b0320","doi-asserted-by":"crossref","first-page":"e0212779","DOI":"10.1371\/journal.pone.0212779","article-title":"The emerging burden of liver disease in cystic fibrosis patients: a UK nationwide study","volume":"14","author":"Toledano","year":"2019","journal-title":"PLoS ONE"},{"issue":"2","key":"10.1016\/j.jcte.2021.100283_b0325","doi-asserted-by":"crossref","first-page":"262","DOI":"10.3390\/jcm10020262","article-title":"Association between liver cirrhosis and diabetes mellitus: a review on hepatic outcomes","volume":"10","author":"Coman","year":"2021","journal-title":"J Clin Med"},{"key":"10.1016\/j.jcte.2021.100283_b0330","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1016\/j.jcf.2019.08.016","article-title":"Cystic fibrosis related diabetes: pathophysiology, screening and diagnosis","volume":"18","author":"Granados","year":"2019","journal-title":"J Cyst Fibros"},{"issue":"6","key":"10.1016\/j.jcte.2021.100283_b0335","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.1016\/j.jhep.2015.08.011","article-title":"Contribution of beta-cell dysfunction and insulin resistance to cirrhosis-associated diabetes: Role of severity of liver disease","volume":"63","author":"Grancini","year":"2015","journal-title":"J Hepatol"},{"issue":"05","key":"10.1016\/j.jcte.2021.100283_b0340","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1055\/s-2005-837546","article-title":"Fasting hyperglucagonemia in patients with transjugular intrahepatic portosystemic shunts (TIPS)","volume":"113","author":"Raddatz","year":"2005","journal-title":"Exp Clin Endocrinol Diabetes"},{"issue":"7","key":"10.1016\/j.jcte.2021.100283_b0345","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.3390\/ijms18071447","article-title":"The role of growth hormone and insulin-like growth factor-I in the liver","volume":"18","author":"Takahashi","year":"2017","journal-title":"Int J Mol Sci"},{"issue":"03","key":"10.1016\/j.jcte.2021.100283_b0350","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1055\/s-2003-39781","article-title":"Effects of free fatty acids (FFA) on glucose metabolism: significance for insulin resistance and type 2 diabetes","volume":"111","author":"Boden","year":"2003","journal-title":"Exp Clin Endocrinol Diabetes"},{"issue":"5","key":"10.1016\/j.jcte.2021.100283_b0355","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1007\/s12072-018-9893-7","article-title":"Metabolic effects of reduced growth hormone action in fatty liver disease","volume":"12","author":"Rufinatscha","year":"2018","journal-title":"Hepatol Int"},{"issue":"2","key":"10.1016\/j.jcte.2021.100283_b0360","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1002\/hep.23719","article-title":"Hepatic lipotoxicity and the pathogenesis of nonalcoholic steatohepatitis: the central role of nontriglyceride fatty acid metabolites","volume":"52","author":"Neuschwander-Tetri","year":"2010","journal-title":"Hepatology"},{"issue":"12","key":"10.1016\/j.jcte.2021.100283_b0365","doi-asserted-by":"crossref","first-page":"3598","DOI":"10.2337\/db16-0649","article-title":"Growth hormone control of hepatic lipid metabolism","volume":"65","author":"Liu","year":"2016","journal-title":"Diabetes"},{"issue":"1","key":"10.1016\/j.jcte.2021.100283_b0370","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1111\/j.1365-2249.1994.tb06609.x","article-title":"Circulating proinflammatory cytokines (IL-1 beta, TNF-alpha, and IL-6) and IL-1 receptor antagonist (IL-1Ra) in fulminant hepatic failure and acute hepatitis","volume":"98","author":"Sekiyama","year":"1994","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.jcte.2021.100283_b0375","doi-asserted-by":"crossref","first-page":"703","DOI":"10.3389\/fendo.2019.00703","article-title":"Cytokines and abnormal glucose and lipid metabolism","volume":"10","author":"Shi","year":"2019","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"Supplement","key":"10.1016\/j.jcte.2021.100283_b0380","article-title":"Islet Function in Youth with Cystic Fibrosis with and without Liver Disease","volume":"1","author":"Rayas","year":"2020","journal-title":"Diabetes"},{"key":"10.1016\/j.jcte.2021.100283_b0385","doi-asserted-by":"crossref","first-page":"S10","DOI":"10.1016\/j.jcf.2019.08.003","article-title":"Cystic fibrosis related diabetes: medical management","volume":"18","author":"Ode","year":"2019","journal-title":"J Cyst Fibros"},{"issue":"4","key":"10.1016\/j.jcte.2021.100283_b0390","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1111\/j.1600-6143.2011.03904.x","article-title":"Long-term impact of liver transplantation on respiratory function and nutritional status in children and adults with cystic fibrosis","volume":"12","author":"Dowman","year":"2012","journal-title":"Am J Transplant"},{"issue":"3","key":"10.1016\/j.jcte.2021.100283_b0395","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1002\/lt.22240","article-title":"Liver transplantation in patients with cystic fibrosis: analysis of United Network for Organ Sharing data","volume":"17","author":"Mendizabal","year":"2011","journal-title":"Liver Transpl"},{"issue":"5","key":"10.1016\/j.jcte.2021.100283_b0400","doi-asserted-by":"crossref","first-page":"1620","DOI":"10.1111\/ajt.13630","article-title":"Under utilization of pancreas transplants in cystic fibrosis recipients in the United Network Organ Sharing (UNOS) data 1987\u20132014","volume":"16","author":"Usatin","year":"2016","journal-title":"Am J Transplant"},{"issue":"1","key":"10.1016\/j.jcte.2021.100283_b0405","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.jcf.2017.05.004","article-title":"Combined lung-liver-pancreas transplantation in a recipient with cystic fibrosis","volume":"17","author":"Barbas","year":"2018","journal-title":"J Cyst Fibros"},{"issue":"3","key":"10.1016\/j.jcte.2021.100283_b0410","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1002\/lt.21070","article-title":"Combined en bloc liver pancreas transplantation for children with CF","volume":"13","author":"Mekeel","year":"2007","journal-title":"Liver Transpl"},{"issue":"01","key":"10.1016\/j.jcte.2021.100283_b0415","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1055\/s-0031-1291288","article-title":"Liver transplantation in children with cystic fibrosis: experience in our centre and preliminary results with a combined en bloc liver-pancreas graft","volume":"22","author":"Miguel","year":"2012","journal-title":"Eur J Pediatr Surg"},{"issue":"4","key":"10.1016\/j.jcte.2021.100283_b0420","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/j.jcf.2013.12.010","article-title":"Simultaneous liver-pancreas transplantation for cystic fibrosis-related liver disease: a multicenter experience","volume":"13","author":"Bandsma","year":"2014","journal-title":"J Cyst Fibros"}],"container-title":["Journal of Clinical & Translational Endocrinology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2214623721000351?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2214623721000351?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T13:58:07Z","timestamp":1762005487000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2214623721000351"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3]]},"references-count":84,"alternative-id":["S2214623721000351"],"URL":"https:\/\/doi.org\/10.1016\/j.jcte.2021.100283","relation":{},"ISSN":["2214-6237"],"issn-type":[{"value":"2214-6237","type":"print"}],"subject":[],"published":{"date-parts":[[2022,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cystic fibrosis related liver disease and endocrine considerations","name":"articletitle","label":"Article Title"},{"value":"Journal of Clinical & Translational Endocrinology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcte.2021.100283","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"100283"}}